secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0000950170-24-002705
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed provides 2024 outlook; GAD Phase 2b showed 7.6-point HAM-A reduction, ADHD trial failed
--------------------------------------------------------------------------------

- MM-120 100µg GAD: 7.6 HAM-A reduction vs placebo (p<0.0004, effect size 0.88); 78% response, 50% remission.
- ADHD Phase 2a sub-perceptual dose trial failed primary endpoint; no further development for that regimen.
- End-of-Phase 2 FDA meeting H1 2024; Phase 3 initiation expected H2 2024 for MM-120 in GAD.
- Full 12-week Phase 2b results for MM-120 in GAD expected by Q1 2024 end.
- Phase 1 for MM-402 (R(-)-MDMA) in ASD started Q4 2023; UHB MDMA trial topline data H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000095017024002705/0000950170-24-002705-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000095017024002705/mnmd-20240108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-002705

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer